Skip to main content
Nature Communications logoLink to Nature Communications
. 2026 Jun 29;17:5628. doi: 10.1038/s41467-026-74645-1

Retraction Note: Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Yunhua Liu 1,2,3,#, Jiangsheng Xu 4,5,#, Hyun Ho Choi 2,#, Cecil Han 2, Yuanzhang Fang 1,2, Yujing Li 1,2, Kevin Van der Jeught 1,2, Hanchen Xu 1,2, Lu Zhang 1,2,3, Michael Frieden 1, Lifei Wang 1, Haniyeh Eyvani 1, Yifan Sun 1, Gang Zhao 6, Yuntian Zhang 4,5, Sheng Liu 1, Jun Wan 1, Cheng Huang 7, Guang Ji 3, Xiongbin Lu 1,2,8,, Xiaoming He 4,5,9,10,, Xinna Zhang 1,8,11,12,
PMCID: PMC13316038  PMID: 42373631

Retraction to: Nature Communications 10.1038/s41467-018-07264-0, published online 09 November 2018

This paper is being retracted after a joint research misconduct investigation conducted by Indiana University, The Ohio State University, and the University of Maryland, College Park found that Figure 5a/b/d/e and Supplementary Fig. 9 contain irregularities. The Editor has therefore lost confidence in this paper.

Yuanzhang Fang did not explicitly state whether or not they agree with this retraction.

Xiongbin Lu, Xinna Zhang, Xiaoming He, Jiangsheng Xu disagree with this retraction.

Yunhua Liu, Hyun Ho Choi, Cecil Han, Yujing Li, Kevin Van der Jeught, Hanchen Xu, Lu Zhang, Michael Frieden, Lifei Wang, Haniyeh Eyvani, Yifan Sun, Gang Zhao, Yuntian Zhang, Sheng Liu, Jun Wan, Cheng Huang, and Guang Ji did not respond to correspondence from the Publisher about this retraction.

Contributor Information

Xiongbin Lu, Email: xiolu@iu.edu.

Xiaoming He, Email: shawnhe@umd.edu.

Xinna Zhang, Email: xz48@iu.edu.


Articles from Nature Communications are provided here courtesy of Nature Publishing Group

RESOURCES